Results 81 to 90 of about 189,087 (191)

Impact of Polyp Regression on 2-year Outcomes of Intravitreal Aflibercept Injections: A Treat-and-Extend Regimen for Polypoidal Choroidal Vasculopathy [PDF]

, 2018
We conducted intravitreal aflibercept injections (IVAs) for 37 Japanese patients (28 males, 9 females, mean age 73.4 years) with polypoidal choroidal vasculopathy (PCV), with a treat-and-extend regimen (TER).
Doi, Shinichiro, Fujiwara, Atsushi, Hirano, Masayuki, Hosogi, Mika, Kimura, Shuhei, Morizane, Yuki, Morizane-Hosokawa, Mio, Shiode, Yusuke, Shiraga, Fumio, Toshima, Shinji   +9 more
core   +1 more source

A treat and extend protocol with Aflibercept for cystoid macular oedema secondary to central retinal vein occlusion – an 18-month prospective cohort study

BMC Ophthalmology, 2020
Background To evaluate the safety and efficacy of a treat-and-extend protocol of aflibercept for cystoid macular oedema (CMO) secondary to central retinal vein occlusion (CRVO).
Roderick O’Day, Noha Ali, Lyndell L. Lim, Sukhpal Sandhu, Thuy Chau, Sanjeewa Wickremasinghe   +5 more
doaj   +1 more source

Efficacy and Safety of Intravitreal Aflibercept Treat-and-Extend Regimens in Exudative Age-Related Macular Degeneration: 52- and 96-Week Findings from ALTAIR : A Randomized Controlled Trial. [PDF]

, 2020
PURPOSE:To evaluate efficacy and safety of intravitreal injections of aflibercept (IVT-AFL) treat-and-extend (T&E) dosing regimens in treatment-naïve patients with exudative age-related macular degeneration (AMD).METHODS:Adults aged at least 50 years old
ALTAIR Investigators, HANEMOTO Tsukasa, HORIGUCHI Masayuki, KAGA Tatsushi, KAWAHARA Akiteru, KIMURA Wataru, KITAMEI Hirokuni, Kobayashi Masato, KOBAYASHI Namie, KOUNO Takeya, KURIMOTO Yasuo, MAENO Takatoshi, MATSUDA Yoshimi, MATSUSHITA Eriko, MIYATA Kazunori, MURAI Kenichi, NISHIMURA Tetsuya, OHJI Masahito, OKADA Annabelle Ayame, SATO Shinpei, SONODA Kohei, TAKAHASHI Kanji, TERANO Yasuhiro, Uchio Eiichi, YANAI Ryoji, YASUKAWA Tsutomu, 大路 正人, 若林 賢彦   +27 more
core   +2 more sources

Real-World Outcomes of Switching to Faricimab in Treatment-Experienced and Resistant Neovascular Age-Related Macular Degeneration: A Single-Centre Retrospective Study

Clinical Ophthalmology
Christopher Stewart,1 Jaskaran Singh Bhangu,2 Parinita Keshav Swarnkar,2 Mohammed Rifat,2 Sarah Khalid,2 Ahmed Al-Janabi,2 Mahmoud H Awad,2 Gwyn Samuel Williams2 1Faculty of Medicine, Health, and Life Science, Swansea University, Swansea, Wales, UK ...
Stewart C, Bhangu JS, Swarnkar PK, Rifat M, Khalid S, Al-Janabi A, Awad MH, Williams GS   +7 more
doaj  

Neovascular Age-Related Macular Degeneration Treated with Aflibercept: Five-Year Follow-Up and Correlation with Optical Coherence Tomography Biomarkers in a Real-World Setting

Ophthalmology and Therapy
Introduction To evaluate long-term outcomes of neovascular age-related macular degeneration(nAMD) treatment with aflibercept in a treat-and-extend (T&E) regimen and explore correlations between optical coherence tomography (OCT) biomarkers and clinical ...
Massimiliano Borselli, Mutasem Elfalah, Teresa Angela Trunfio, Arianna Scala, Domenico Chisari, Alessandra Mancini, Andrea Lucisano, Giovanna Carnovale-Scalzo, Vincenzo Mollace, Giovanni Improta, Sandrine Zweifel, Vincenzo Scorcia, Mario Damiano Toro, Adriano Carnevali   +13 more
doaj   +1 more source

Comparison of two individualized treatment regimens with ranibizumab for diabetic macular edema. [PDF]

, 2016
PURPOSE To compare outcomes between an as-needed and a treat-and-extend regimen in managing diabetic macular edema with intravitreal ranibizumab. METHODS This was a retrospective, single-centre, comparative case series on 46 treatment naive ...
Ebneter, Andreas, Waldmeier, Dominik, Wolf, Sebastian, Zinkernagel, Martin, Zysset-Burri, Denise Corinne   +4 more
core   +1 more source

Anatomical and functional response after conversion to aflibercept using the treat-and-extend regimen protocol in bevacizumab treatment-resistant wet age-related macular degeneration

Clinical Ophthalmology, 2018
Claudia Taipale,1,2 Ilkka Laine,1,3 Raimo Tuuminen1,3 1Helsinki Retina Research Group, Medicum, Faculty of Medicine, University of Helsinki, Helsinki, Finland; 2Department of Ophthalmology, Helsinki University Hospital, Helsinki, Finland; 3Department of
Taipale C, Laine I, Tuuminen R
doaj  

Comparative study on the efficacy of different aflibercept regimens in the treatment of macular edema secondary to branch retinal vein occlusion

Frontiers in Medicine
ObjectivesTo compare the efficacy of intravitreal injection of aflibercept between the treat-and-extend (TAE) and pro re nata (PRN, as needed) regimens in the treatment of macular edema secondary to branch retinal vein occlusion, to determine the best ...
Xing Du, Yuanyuan Guo, Min Du, Wen Wang, Mingkun Liu, Shanshan Li, Yanjuan Sheng   +6 more
doaj   +1 more source

Anatomical and functional response after conversion to aflibercept using the treat-and-extend regimen protocol in bevacizumab treatment-resistant wet age-related macular degeneration [PDF]

, 2019
Objective: To evaluate the functional and anatomical response after the switch from bevacizumab to aflibercept in treatment-resistant wet age-related macular degeneration (wAMD) using the treat-and-extend regimen protocol.
Laine, Ilkka, Taipale, Claudia, Tuuminen, Raimo   +2 more
core   +1 more source

Five-year outcomes of intravitreal drug therapy for neovascular age-related macular degeneration in eyes with baseline vision 20/60 or better

Clinical Ophthalmology, 2019
Arshad M Khanani,1 Greggory M Gahn,2 Micaela M Koci,2 Jonathan M Dang,2 Sandra M Brown,3 Lauren F Hill4 1Sierra Eye Associates, Reno, NV, USA; 2School of Medicine, University of Nevada, Reno, NV, USA; 3Cabarrus Eye Center, Concord, NC, USA; 4Hill  ...
Khanani AM, Gahn GM, Koci MM, Dang JM, Brown SM, Hill LF   +5 more
doaj